Laurence Zitvogel

Centre National de la Recherche Scientifique

Papers

Total Citations

129

H-Index

About

Laurence Zitvogel is a pioneering figure in cancer immunology, renowned for her groundbreaking work on immunogenic cell death (ICD) and the mechanisms by which anticancer therapies engage the immune system. Her research has fundamentally reshaped our understanding of how certain treatments—including chemotherapies, oncolytic peptides, and targeted agents—can transform dying tumor cells into potent vaccines that activate T cell-mediated immunity. Among her most cited contributions is the discovery that the oncolytic peptide LTX-315 triggers ICD by permeabilizing mitochondrial membranes, leading to caspase-independent necrosis and a robust antitumor immune response (129 citations). This work exemplifies her broader impact: Zitvogel has helped define the molecular hallmarks of ICD, including the critical roles of calreticulin exposure, ATP secretion, and HMGB1 release. With over 70,000 citations and numerous awards, including the prestigious Inserm Grand Prix, she continues to lead translational studies that bridge basic immunology and clinical oncology, offering new strategies to improve immunotherapy outcomes for cancer patients.